CYP3A4 and cancer: The present study is the first to support the notion that the inhibition of KCa1.1 may manipulate CYP3A4, which is involved in the metabolism of many anti-cancer drugs and revealed the KCa1.1 inhibition-mediated overcoming DOX resistance in KCa1.1 overexpressing cancer spheroid models.